Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...
Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...
The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...
(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
I spent four crazy years writing about Cassava Sciences. Yesterday, the story ended exactly as I and many others knew it ...
For more information on the foundation and more insight into what we can all do to support those suffering from these ...
ScienceAlert on MSN20h
Nasal Spray May Slow Alzheimer's Disease, Study in Mice SuggestsThe active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback